B. Li

Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers

J. Chiu, T. Yau, A. Kwong, 2021, Advances in Therapy.

Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.

J. Chiu, T. Yau, T. Cheung, 2019, Journal of Clinical Oncology.

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

J. Chiu, T. Yau, C. Lo, 2021, Journal for ImmunoTherapy of Cancer.

Thyroid Immune-Related Adverse Events in Cancer Patients Treated with Anti-PD1/Anti-CTLA4 Immune-Checkpoint Inhibitor Combination: Clinical Course and Outcomes.

J. Chiu, T. Yau, T. Cheung, 2021, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Nivolumab/pembrolizumab in Child-Pugh grade B/C patients with advanced HCC.

J. Chiu, T. Yau, T. Cheung, 2021 .

Integrated palliative medicine in public oncology: a 10-year review

T. Lam, M. Tong, K. Wong, 2021, BMJ supportive & palliative care.

Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib

J. Chiu, T. Yau, T. Cheung, 2021, Expert review of gastroenterology & hepatology.

Integrative Palliative Care Service Model Improved End-of-Life Care and Overall Survival of Advanced Cancer Patients in Hong Kong: A Review of Ten-Year Territory-Wide Cohort.

R. Lo, T. Lam, M. Tong, 2021, Journal of palliative medicine.